EOLS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Evolus Inc (EOLS) is not a strong buy for a beginner investor with a long-term strategy at this time. The stock's technical indicators are mixed, with bearish moving averages and neutral RSI. Insider selling has increased significantly, and financial performance shows declining net income and EPS. Analysts have lowered price targets, reflecting a cautious outlook. While the company has shown revenue growth, the lack of positive catalysts and weak sentiment in the options market suggest holding off on investment for now.
The MACD is positive and expanding, indicating a potential bullish momentum. However, RSI is neutral at 57.903, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level of 4.374, with resistance at 4.515 and support at 4.233.
The company's revenue increased by 12.90% YoY in Q3 2025, indicating some growth potential.
Insider selling has increased by 113% over the last month, and analysts have lowered price targets due to a weaker outlook for the aesthetic injectables market. Additionally, net income and EPS have declined significantly YoY.
In Q3 2025, revenue increased to $68.97M (up 12.90% YoY), but net income dropped to -$15.74M (down 17.91% YoY), and EPS fell to -0.24 (down 20.00% YoY). Gross margin also declined to 64.03% (down 6.38% YoY).
Analysts have lowered price targets recently: Mizuho reduced the target to $15 from $19, and BTIG reduced it to $13 from $18. Both firms maintain positive ratings but reflect a cautious outlook due to market challenges.
